clinical trial · NCT06308926
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
Acute Respiratory Distress SyndromeRespiratory FailureRespiratory Distress SyndromeRespiratory Tract DiseasesCytokine StormMRG-001 (Low-dose)MRG-001 (High-dose)Placebo
brief summary
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
started
Dec 1, 2024
primary completion
Feb 1, 2026
completion
Jul 1, 2026
last updated
Aug 23, 2024
official title
A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol